Holen Sie sich die Stockscreener-App
3.05
0.33%
-0.01
Handel nachbörslich:
3.12
0.07
+2.30%
Cervomed Inc Aktie (CRVO) Neueste Nachrichten
CRVO Q1 2026 Earnings: EPS Misses EstimatesProfit Margin Analysis - Newser
CRVO Q1 2026 Earnings: EPS Miss Reflects Continued Clinical InvestmentReal Trader Network - Newser
CervoMed Stock Slides Into Long Weekend as CRVO’s Cash Clock Tests Phase 3 Hopes - Bez Kabli
CervoMed Inc. (CRVO) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Stock DeclineNet Profit Margin - Newser
CRVO Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Clinical Stage Company Reports No RevenueEarnings Momentum Score - Newser
What CervoMed (CRVO)'s -2.75% Decline Means for Investors 2026-05-21Put Dominated - Newser
CervoMed (CRVO) Q1 2026 Results Fall Short — EPS $-0.86, Revenue $N/AAnnual Financial Report - Newser
CervoMed Inc. Announces Q1 2026 Financial Results, Corporate Updates, and Phase 3 DLB Trial Plans - Minichart
How to Value CervoMed (CRVO) After Q1 2026? EPS Not Disclosed; R - GuruFocus
CervoMed Expects EXPERTS-ALS to Dose First Patient With ALS With Neflamapimod by End of 2026 >CRVO - Moomoo
CervoMed Highlights Q1 Results and Neflamapimod Progress - TipRanks
CervoMed (NASDAQ: CRVO) posts Q1 2026 loss and cash runway into Q3 2026 - Stock Titan
CervoMed (CRVO) Reports Significant Decline in Grant Revenue and Increased Net Loss - GuruFocus
CervoMed posts smaller-than-expected Q1 net loss - TradingView
Press Release: CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates - Moomoo
CervoMed announced plans to initiate a Phase III clinical trial in the second half of 2026 to evaluate the efficacy and safety of its candidate drug Neflamapimod in patients with dementia with Lewy bodies (DLB). - Bitget
Number of shareholders of CervoMed Inc. – NASDAQ:CRVO - TradingView
CervoMed Inc. Q1 2026 10-Q: Financial Results, Risk Factors, and Forward-Looking Statements Overview - Minichart
CervoMed Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CervoMed Inc. 1Q 2026: Revenue $0 Net income ($7.96M), EPS ($0.86) — 10-Q Summary - TradingView
CRVO: Net loss increased to $8.0 million in Q1 2026, with cash runway concerns due to lack of new funding - TradingView
CervoMed Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
CervoMed (CRVO) widens quarterly loss and warns of going concern risk - Stock Titan
CRVO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
CRVO Stock Price, Quote & Chart | CERVOMED INC (NASDAQ:CRVO) - ChartMill
Morgan Stanley reporting units hold 8.0% of CervoMed (CRVO) in Schedule 13G/A - Stock Titan
CervoMed Inc expected to post a loss of 78 cents a shareEarnings Preview - TradingView
What CervoMed (CRVO) is doing to stay ahead (Breakdown Watch) 2026-05-08Community Momentum Stocks - newser.com
CervoMed (CRVO) outlines 2026 virtual meeting, board slate and pay plan vote - Stock Titan
[ARS] CervoMed Inc. SEC Filing - Stock Titan
CRVO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
CRVO (CervoMed) posts wider than expected Q4 2025 loss even as shares notch mild daily gains.Crowd Risk Alerts - Newser
H.C. Wainwright Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $25 - Moomoo
CRVO Maintained by D. Boral Capital -- Price Target Steady at $3 - GuruFocus
CervoMed Highlights Positive Phase 2b Neflamapimod MRI Results - TipRanks
CRVO (CervoMed Inc.) reports wider-than-expected Q4 2025 loss driven by elevated clinical research spending.Decline Phase - Cổng thông tin điện tử Tỉnh Sơn La
Neflamapimod MRI data in dementia with Lewy bodies from CervoMed (NASDAQ: CRVO) - Stock Titan
CervoMed (CRVO) Shows Promise in DLB Treatment with Neflamapimod - GuruFocus
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies - ChartMill
Drug candidate boosted brain region tied to Lewy body dementia - Stock Titan
What should investors watch for CervoMed (CRVO) stock (Smart Money Exits) 2026-04-20Public Sentiment - Cổng thông tin điện tử tỉnh Lào Cai
Is CervoMed (CRVO) stock a good candidate for diversification (Investor Concern) 2026-04-18Community Pattern Alerts - Xã Châu Thành
Operating cash flow per share of CervoMed Inc. – FWB:DP8 - TradingView — Track All Markets
CRVO Should I Buy - Intellectia AI
CRVO.O PE Ratio & Valuation, Is CRVO.O Overvalued - Intellectia AI
CRVO.O Forecast — Price Prediction for 2026. Should I Buy CRVO.O? - Intellectia AI
Buyout Rumor: Does CervoMed Inc have strong fundamentalsWeekly Stock Analysis & Verified Momentum Watchlists - baoquankhu1.vn
CRVO.O Technical Analysis & Stock Price Forecast - Intellectia AI
CRVO.O Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Lewy Body Dementia Market: Accelerating Growth And Pipeline Impact By 2034 Delveinsight Cognition Therapeutics, Keiferx, Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics - Mena FN
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):